Literature DB >> 9551990

Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors.

G Noffz1, Z Qin, M Kopf, T Blankenstein.   

Abstract

Local expression of IL-4 by gene-modified tumor cells increases their immunogenicity by inducing an inflammatory response that is dominated by eosinophils. Eosinophils have been implicated as antitumor effector cells because the application of a granulocyte-depleting Ab inhibited rejection of IL-4 transfected tumors. This Ab did not discriminate between eosinophils and neutrophils and, therefore, this experiment could not exclude neutrophils as primary effector cells, whereas eosinophils were innocent bystander cells in IL-4 transfected tumors. We analyzed tumor growth suppression and granulocyte infiltration in IL-5-deficient (IL-5(-/-)) mice that had a deficiency of eosinophils, using two tumor lines (B16-F10 and MCA205) transfected to secrete IL-4. IL-4-expressing tumors were at least as efficiently rejected in IL-5(-/-) mice as in wild-type mice, despite an almost complete absence of tumor-infiltrating eosinophils. However, neutrophils were present in undiminished amounts and their depletion partially restored tumor growth. Furthermore, the growth of IL-5-secreting tumors was not impaired in either wild-type or IL-5(-/-) mice, even though it induced eosinophilia in both mouse strains. These findings demonstrate that eosinophils can be induced in IL-5(-/-) mice by exogenous IL-5 and argue against a compensatory effect of neutrophils in the absence of eosinophils. We conclude that 1) infiltration of IL-4 transfected tumors by eosinophils is completely IL-5 dependent, 2) eosinophils have no tumoricidal activity, and 3) neutrophils are responsible, at least in part, for tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551990

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth.

Authors:  S Pacor; R Gagliardi; P Spessotto; G Zabucchi; G Sava
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 3.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 4.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

Review 5.  Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Authors:  Hao-Wei Wang; Johanna A Joyce
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

6.  Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response.

Authors:  Stephania A Cormier; Anna G Taranova; Carrie Bedient; Thanh Nguyen; Cheryl Protheroe; Ralph Pero; Dawn Dimina; Sergei I Ochkur; Katie O'Neill; Dana Colbert; Theresa R Lombari; Stephanie Constant; Michael P McGarry; James J Lee; Nancy A Lee
Journal:  J Leukoc Biol       Date:  2006-04-14       Impact factor: 4.962

7.  Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Authors:  Rafael Carretero; Ibrahim M Sektioglu; Natalio Garbi; Oscar C Salgado; Philipp Beckhove; Günter J Hämmerling
Journal:  Nat Immunol       Date:  2015-04-27       Impact factor: 25.606

8.  Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.

Authors:  Michael Samoszuk; Tom Deng; Mark J Hamamura; Min-Ying Su; Nicholas Asbrock; Orhan Nalcioglu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 9.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  Tumor rejection by modulation of tumor stromal fibroblasts.

Authors:  Thomas Schüler; Sandra Körnig; Thomas Blankenstein
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.